Tumour Jagged1 expression as a prognostic marker of bevacizumab response and modulation of 5-fluorouracil efficacy through γ-secretase inhibition in colorectal cancer
High tumour JAG1 expression identifies metastatic CRC patients with poorer outcomes when treated with a bevacizumab-containing regimen, supporting its potential as a prognostic biomarker. Mechanistically, Notch inhibition enhances the antitumour effects of 5-FU, suggesting that its combination with γ-secretase inhibitors may improve therapeutic efficacy in CRC.
Authors
- Octavio Caba (ORCID: https://orcid.org/0000-0003-3426-8294)
- Consolación Melguizo (ORCID: https://orcid.org/0000-0003-3990-806X)
- Julia Jiménez-López (ORCID: https://orcid.org/0000-0003-4659-4070)
- R. Ortiz
- Olga María García-Valdeavero
- José Prados
- Cristina Jiménez-Luna
- Encarnación Gonzalez-Flores
Institutions
- Instituto de Bioquímica Vegetal y Fotosíntesis (ES)
- Instituto de Investigación Biosanitaria de Granada (ES)
- Hospital Universitario Virgen de las Nieves (ES)
- Department of Embryology (US)
- Regenerative Medicine Institute (MX)
- Centro de Investigaciones Científicas Isla de la Cartuja (ES)
- Hospital Central de las Fuerzas Armadas (UY)
Publication Details
- Journal
- Gastroenterology report
- Published
- 2026-01-20
- DOI
- https://doi.org/10.1093/gastro/goag012
- Primary Topic
- Developmental Biology and Gene Regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Universidad de Granada
- Instituto de Salud Carlos III